Answers are grounded in this paper and cite their sources.
This article estimates hidden operational and financial costs of regulatory changes in dermatology, suggesting better evaluation of interventions.
This article estimates the hidden operational and financial cost of repeated isotretinoin regulatory change across UK dermatology services following the MHRAs 2023 and 2026 guidance cycles. Using transparent, conservative assumptions, it argues that substantial clinical, governance, and organisational resource was diverted from patient care and that future regulatory interventions should be evaluated not only for safety intent, but also for implementation burden and opportunity cost.
No takes yet. Share an insight, caveat, or question.
James Denny (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: